Nevada Canyon Gold Corp. (NGLD)

CTI BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6.73	7.04	9.74	1.01	1.42	0.89
Cash & Short-Term Investments	6.73	7.04	9.74	1.01	1.42	0.89
Cash Growth	-30.22%	-27.79%	867.65%	-29.13%	58.97%	143.41%
Other Receivables	-	0	-	-	-	-
Receivables	-	0.2	-	-	-	-
Prepaid Expenses	0.49	0.31	0.54	0	0.02	0
Total Current Assets	7.22	7.55	10.29	1.01	1.44	0.9
Property, Plant & Equipment	2.82	2.82	0.78	0.72	0.27	0.01
Long-Term Investments	0.06	0.06	0.06	0.16	0.32	0.79
Total Assets	10.09	10.42	11.12	1.89	2.03	1.7
Accounts Payable	0.85	0.85	0.85	0.84	0.37	0.35
Accrued Expenses	-	-	-	-	0.03	0.01
Short-Term Debt	-	-	-	-	0.43	0.02
Other Current Liabilities	0.46	0.46	0.46	0.48	0.96	1.06
Total Current Liabilities	1.31	1.31	1.31	1.32	1.79	1.43
Total Liabilities	1.31	1.31	1.31	1.32	1.79	1.43
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	18.39	17.83	14.96	3.07	1.19	0.53
Retained Earnings	-9.61	-8.72	-5.16	-2.51	-0.95	-0.26
Comprehensive Income & Other	0	0	0.02	-	-	-
Shareholders' Equity	8.79	9.11	9.82	0.57	0.24	0.27
Total Liabilities & Equity	10.09	10.42	11.12	1.89	2.03	1.7
Total Debt	-	-	-	-	0.43	0.02
Net Cash (Debt)	6.73	7.04	9.74	1.01	0.99	0.88
Net Cash Growth	-30.22%	-27.79%	867.65%	1.80%	12.71%	150.02%
Net Cash Per Share	0.25	0.27	0.77	0.33	0.22	0.20
Filing Date Shares Outstanding	27.98	27.65	23.32	7.07	2.68	4.46
Total Common Shares Outstanding	27.98	27.42	23.24	7.07	2.68	4.46
Working Capital	5.91	6.23	8.98	-0.31	-0.35	-0.54
Book Value Per Share	0.31	0.33	0.42	0.08	0.09	0.06
Tangible Book Value	8.79	9.11	9.82	0.57	0.24	0.27
Tangible Book Value Per Share	0.31	0.33	0.42	0.08	0.09	0.06

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.